Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
3rd September 2008
MUNICH, Germany, September 3 /PRNewswire/ -- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment
with prasugrel compared with clopidogrel significantly reduced the risk of
new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001),
regardless of whether the events occurred around the time of an
artery-opening procedure known as percutaneous coronary intervention (PCI),
or if they occurred spontaneously during the longer-term maintenance phase.
The analysis was...
more
South America - Pharma Events Confirmed for This Year and 2009
16th July 2008
LONDON, July 16 /PRNewswire/ -- CMPi events for the fast-developing pharma markets of South and Latin
America debut next month. Rio de Janeiro will host the twin launch of the
CPhI South America pharma ingredients and P-MEC South America pharma
machinery and equipment exhibitions on Tuesday 19 - Thursday 21 August. Sao
Paulo will then host the 2009 events.
The launch exhibitions will be held at Brazil's newest convention
facility -- the Centro de Convencoes Sulamerica at Cidade Nova, opened...
more